. Inducible, sustained, monomorphic ventricular tachycardia at a cycle length of 230 ms during focused electrophysiological testing.
A 36-year-old asymptomatic white woman with hypertrophic cardiomyopathy (HCM) was referred for electrophysiological assessment. 1 She was heterozygous for the missense mutation 275GϾA (R92Q) in exon 9 of the cardiac troponin T gene (TNNT2) that has been previously reported to be strongly associated with HCM. 2, 3, 4 She also had a significant family history of HCM, including sudden cardiac death of 1 son with autopsy confirmation of HCM and phenotypic HCM in 2 others. Her 2 surviving children, both with left ventricular hypertrophy, had already received implantable cardioverter-defibrillators and both have had multiple appropriate device discharges. Repeat echocardiograms in our patient had consistently demonstrated normal left ventricular structure and systolic function. Cardiovascular magnetic resonance (CMR) assessment similarly confirmed normal left ventricular systolic function and wall thickness but uniquely showed extensive late gadolinium enhancement (LGE) throughout the left ventricle ( Figure 1 ). The constellation of her strongly positive family history, positive genotype, and CMR findings prompted concerns for her risk of sudden cardiac death.
During a comprehensive electrophysiological study, straight atrial pacing confirmed normal sinus node and atrioventricular node functions with no inducible supraventricular arrhythmias. However, programmed ventricular stimulation with double ventricular extrastimuli from the right ventricular outflow tract induced fast, sustained, monomorphic ventricular tachycardia at cycle length of 230 ms ( Figure 2 ). This arrhythmia spontaneously degenerated into ventricular fibrillation and was subsequently converted to sinus rhythm with 300 J of biphasic energy. The patient has been scheduled for placement of an implantable cardioverter-defibrillator. 5 Myocardial scar in HCM is classically described as occurring at the "right ventricular insertion points" (ie, the junctions of the right ventricular free wall and the interventricular septum). 6 Diffuse LGE on CMR without left ventricular hypertrophy or enlargement in HCM was unknown until recent description in our previous report of this patient. 1 LGE commonly represents myocardial fibrosis and, therefore, may be a harbinger for serious sequelae such as sudden cardiac death and malignant arrhythmias. 7, 8 Myocardial scar and, in particular, "watershed areas" at the interface of scarred and healthy myocardium are also known substrates for electrical instability, where in postmyocardial patients it confers added prognostic value for risk stratification. 9 Moreover, in those with nonischemic and infiltrative cardiomyopathy, 8 there has been evidence that the presence of LGE provides incremental prognostic value for predicting major adverse cardiovascular events.
In this particular case, electrophysiological assessment was extremely helpful in appropriately risk stratifying our patient and determining further therapy. This is the first known case 
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that has demonstrated inducible malignant arrhythmia in an otherwise asymptomatic patient with HCM where repeated cardiovascular imaging had shown normal left ventricular wall thickness and dimensions, and in whom LGE on CMR had demonstrated diffuse myocardial scar. Importantly, with certain types of HCM genotypes, such as that noted in our patient, heterozygotes for the missense mutation 275GϾA (R92Q) in exon 9 of cardiac TNNT2 are susceptible to malignant arrhythmias irrespective of presence or absence of the phenotypic manifestations of HCM. 3, 4 Such susceptibility is perhaps further heightened with the presence of diffuse myocardial scar. Further focused evaluation of the need to include LGE CMR and electrophysiological assessment as routine practice to screen similar atypical patients with genotypic HCM but without cardiac hypertrophy is required.
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